Skip to content

Corcept Therapeutics

US · CORT #1285 by market cap Listed 1970
63.62 -1.36 -2.09%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 65.43 +0.70%
After-hours 63.62 0.00%
123.5760.3663.622026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CORT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -31.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 8.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A-
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 47.8x Better than 10%
Forward P/E 13.4x Better than 62%
Price / Sales 8.3x Better than 13%
P/E vs own 5-yr range 74th pctl Better than 35%
Growth B

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 23.7% Better than 86%
Net income CAGR (3Y) -0.6% Better than 40%
Free cash flow CAGR (3Y) 5.7% Better than 46%
Profitability B+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 98.3% Better than 99%
Operating margin 5.9% Better than 38%
Net margin 12.9% Better than 67%
Return on equity 14.8% Better than 68%
Return on invested capital 12.2% Better than 76%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -48.0% Better than 6%
6-month return 5.6% Better than 66%
12-month return (ex latest month) 39.1% Better than 77%
Distance below 52-week high 49.7% Better than 19%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.9x Better than 72%
Debt to assets 0.7% Better than 94%
Interest coverage 1,078.7x Better than 98%
Free cash flow / net income 142.3% Better than 62%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 160.5% Better than 91%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.78%
1M -45.37%
3M -47.44%
6M +7.72%
YTD +82.82%
1Y -15.23%
3Y +145.26%
5Y +178.18%

Key statistics

Price & volume

Prev close
64.98
Open
64.07
Day range
62.81 - 65.13
Avg price
63.67
Volume
1.09M
Turnover
69.47M
Amplitude
3.57%
52-week range
28.66 - 126.38

Valuation

P/E
77.59
P/E (TTM)
47.83
P/B
8.35
EPS
0.82
Net profit
89.74M
Net assets
833.74M

Share structure

Market cap
6.96B
Float cap
6.22B
Shares out
109.44M
Float shares
97.83M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 36% of range
28.66 126.38

49.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-35.63M net over the window

Short interest

Shares short
9.13M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Corcept Therapeutics (CORT)?

Corcept Therapeutics last traded at 63.62. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Corcept Therapeutics's market cap?

About 6.96B.

What is the P/E ratio of Corcept Therapeutics?

The trailing twelve-month P/E is 47.83, below its own 5-year average of 58.48 — toward the top of its historical range (73.55% percentile). See the Valuation tab for the full history.

Does Corcept Therapeutics pay a dividend?

Corcept Therapeutics does not currently pay a regular dividend.

Is Corcept Therapeutics a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 165.75, which implies 160.5% upside from the current price. This is not investment advice.

What is Corcept Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Corcept Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Corcept Therapeutics discussion 0 comments

Add a comment